EFNA3 Protein: Mechanisms, Pathological Roles and Translational Research Potential.

Concept

Ephrin A3 (EFNA3), a key member of the ephrin-A ligand subfamily, exerts biological functions through specific interactions with EphA receptor tyrosine kinases—the largest family of such receptors in the human genome. As a glycosylphosphatidylinositol (GPI)-anchored membrane protein, EFNA3 features a conserved structural architecture that mediates bidirectional Eph/ephrin signaling, governing a spectrum of physiological processes from embryonic development and tissue homeostasis to intercellular communication.

Aberrant EFNA3 expression and dysregulated EFNA3-EphA signaling are closely linked to the onset and progression of multiple human malignancies, making EFNA3 a promising therapeutic target for cancer research. Recombinant EFNA3 protein, a core research tool developed by ANT BIO PTE. LTD.’s UA sub-brand (specializing in recombinant proteins), has become an indispensable asset for elucidating EFNA3’s molecular mechanisms, validating its therapeutic potential and advancing translational cancer research.

Research Frontier

Recent advances in Eph/ephrin signaling research have highlighted the multifaceted role of EFNA3 in both normal physiology and disease pathogenesis, with a surge in studies focusing on its oncogenic functions and clinical translational potential. Cutting-edge research has confirmed that EFNA3 is frequently overexpressed in a broad range of solid tumors, including gastric, lung, hepatocellular, colorectal and breast cancer, and its expression level serves as an independent prognostic biomarker for cancer patients.

A key research breakthrough in this field is the identification of EFNA3’s dual role in regulating tumor cell intrinsic properties and the tumor immune microenvironment (TIME): EFNA3 not only enhances tumor cell proliferation, invasion and metastasis by activating downstream oncogenic signaling pathways, but also modulates immune cell infiltration to facilitate tumor immune escape. Additionally, emerging evidence has established a correlation between EFNA3 expression and the efficacy of immune checkpoint inhibitors, opening new avenues for combinatorial cancer therapies targeting EFNA3 and immune checkpoints.

The development of high-purity, bioactive recombinant EFNA3 protein has been pivotal to these discoveries, enabling in-depth structural characterization, functional validation and high-throughput drug screening for EFNA3-targeted therapeutics. ANT BIO PTE. LTD. has leveraged advanced recombinant protein expression technology to develop a series of human EFNA3 recombinant proteins with different tags and modifications, meeting the diverse needs of cutting-edge EFNA3 research.

Research Significance

Elucidating the biological functions and molecular mechanisms of EFNA3 holds profound significance for both basic life science research and clinical cancer therapy development, with three core research values:

1. Advancing Developmental Biology Research: EFNA3 is a key regulator of axon guidance, tissue morphogenesis and synaptic formation during embryonic development. In-depth study of EFNA3 provides critical insights into the molecular mechanisms of nervous system development and intercellular communication, enriching our understanding of human developmental biology.
2. Uncovering Oncogenic Mechanisms: The identification of EFNA3 as an oncogenic factor and prognostic biomarker reveals new molecular pathways underlying tumor initiation and progression, filling the knowledge gap in cancer cell biology and tumor microenvironment regulation.
3. Driving Translational Cancer Therapy: EFNA3’s role as a functional oncogene and immune modulator makes it a novel and promising therapeutic target. Research on EFNA3 paves the way for the development of monoclonal antibodies, small molecule inhibitors and combinatorial immunotherapies, offering new treatment options for patients with EFNA3-overexpressing cancers.
4. Optimizing Cancer Prognosis and Treatment Stratification: EFNA3 expression levels can serve as a reliable prognostic biomarker and a predictive marker for immune checkpoint inhibitor efficacy, enabling personalized cancer prognosis assessment and treatment stratification to improve clinical treatment outcomes.

Recombinant EFNA3 protein is the foundational tool for all the above research directions, and the availability of high-quality EFNA3 recombinant proteins directly determines the depth and reliability of EFNA3-related research.

Related Mechanisms and Product Applications

Core Mechanisms of EFNA3: Structure, Physiological Functions and Oncogenic Signaling

1. Structural Features of EFNA3

EFNA3 is a GPI-anchored membrane protein belonging to the ephrin-A subfamily, with a three-domain structural architecture that dictates its biological activity:

• N-terminal signal peptide: Facilitates the correct intracellular transport and membrane localization of EFNA3, a prerequisite for its cell surface signaling functions.
• Ephrin homology domain: The highly conserved core functional domain that mediates specific binding to EphA receptors, initiating bidirectional Eph/ephrin signaling.
• GPI-anchored domain: Anchors EFNA3 to the cell membrane and enables its shedding from the cell surface to generate soluble EFNA3, which exerts paracrine and autocrine effects in the tumor microenvironment.

2. Physiological and Pathological Functions of EFNA3

Physiological functions: EFNA3 is essential for normal biological processes, including axon guidance in nervous system development, regulation of cell adhesion and migration for tissue morphogenesis and wound healing, synaptic formation and maintenance in the brain, and modulation of cell-matrix interactions to regulate cell shape and motility.

Pathological (oncogenic) functions: In cancer, aberrant EFNA3 overexpression drives multiple malignant phenotypes:

• Promotes tumor cell invasion and metastasis by enhancing cell migratory and invasive capabilities.
• Induces tumor immune escape by reducing the infiltration of anti-tumor immune cells (CD8⁺ T cells, dendritic cells, B cells, etc.) in the TIME.
• Correlates with poor clinical prognosis, including reduced overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) in cancer patients.

3. EFNA3-Mediated Oncogenic Signaling Pathways

EFNA3 activates a cascade of downstream oncogenic signaling pathways upon binding to EphA receptors, which cooperate to drive tumorigenesis and progression:

• Ras signaling pathway: Promotes tumor cell proliferation and anti-apoptotic survival.
• Rap1 signaling pathway: Regulates cell adhesion and cytoskeletal rearrangement to enhance tumor cell migration and invasion.
• PI3K/Akt signaling pathway: Augments tumor cell metabolism, proliferation and survival, and contributes to drug resistance.

Recombinant EFNA3 Protein from ANT BIO PTE. LTD.: Applications and Research Value

ANT BIO PTE. LTD.’s UA sub-brand, a specialist in high-quality recombinant proteins, offers a diverse portfolio of human EFNA3 recombinant proteins expressed in the HEK293 system—one of the most reliable eukaryotic expression systems for producing bioactive human proteins with correct post-translational modifications. These products cover different tag modifications (Fc, His, Biotinylated Fc&Avi) to meet the diverse experimental needs of EFNA3 research, and have been validated for high purity, bioactivity and batch-to-batch consistency.

Key Research Applications of Recombinant EFNA3 Protein

1. Structural biology studies: High-purity recombinant EFNA3 is used in X-ray crystallography and cryo-electron microscopy to resolve the 3D structure of EFNA3 and its complex with EphA receptors, elucidating the molecular basis of ligand-receptor binding.
2. In vitro cell function assays: Used to stimulate cancer and normal cell lines to investigate EFNA3’s effects on cell proliferation, migration, invasion and apoptosis, validating its oncogenic functions and underlying mechanisms.
3. Immunoassay development: Serves as a coating antigen in ELISA and other immunoassays to detect EFNA3-specific antibodies in clinical patient samples, supporting the development of EFNA3-based diagnostic assays.
4. High-throughput drug screening: Used as a key reagent in high-throughput screening platforms to identify small molecule inhibitors, neutralizing antibodies and other therapeutic molecules that block EFNA3-EphA binding or inhibit downstream signaling.
5. In vivo preclinical research: Administered in animal cancer models to study EFNA3’s in vivo effects on tumor growth, metastasis and immune microenvironment, providing preclinical evidence for EFNA3-targeted therapy development.
6. Receptor-ligand interaction studies: Enables quantitative analysis of the binding affinity between EFNA3 and different EphA receptors, clarifying the receptor specificity of EFNA3 signaling.

Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.